MF Yuen

447 total citations
34 papers, 370 citations indexed

About

MF Yuen is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, MF Yuen has authored 34 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Epidemiology, 23 papers in Hepatology and 7 papers in Infectious Diseases. Recurrent topics in MF Yuen's work include Hepatitis B Virus Studies (26 papers), Hepatitis C virus research (21 papers) and Liver Disease Diagnosis and Treatment (15 papers). MF Yuen is often cited by papers focused on Hepatitis B Virus Studies (26 papers), Hepatitis C virus research (21 papers) and Liver Disease Diagnosis and Treatment (15 papers). MF Yuen collaborates with scholars based in Hong Kong, China and United States. MF Yuen's co-authors include Ching‐Lung Lai, Benjamin CY Wong, Cindy Lo Kuen Lam, Dyt Fong, Elegance T. P. Lam, F. M. Y. Fung, C. K. Chan, A. Chan, Harry Hua‐Xiang Xia and Chee Kin Hui and has published in prestigious journals such as Gastroenterology, Journal of Hepatology and The American Journal of Gastroenterology.

In The Last Decade

MF Yuen

31 papers receiving 354 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
MF Yuen Hong Kong 11 216 201 133 74 47 34 370
A.S. Lok United States 9 188 0.9× 194 1.0× 78 0.6× 44 0.6× 27 0.6× 19 298
Samah Soliman Egypt 11 164 0.8× 176 0.9× 138 1.0× 29 0.4× 42 0.9× 18 297
Michael K. K. Li China 8 204 0.9× 197 1.0× 319 2.4× 173 2.3× 109 2.3× 13 503
M. Forné Spain 9 258 1.2× 189 0.9× 221 1.7× 133 1.8× 35 0.7× 15 406
Blai Dalmau Spain 9 145 0.7× 153 0.8× 142 1.1× 34 0.5× 23 0.5× 31 262
Jérôme Filippi France 6 149 0.7× 122 0.6× 121 0.9× 91 1.2× 34 0.7× 8 328
Nasir Hassan Luck Pakistan 9 118 0.5× 93 0.5× 94 0.7× 49 0.7× 37 0.8× 65 266
Rekha Cheruvattath United States 7 201 0.9× 234 1.2× 166 1.2× 28 0.4× 49 1.0× 8 370
Andrew Kirk United Kingdom 5 195 0.9× 200 1.0× 126 0.9× 32 0.4× 37 0.8× 6 342
Jaya Agarwal India 8 111 0.5× 68 0.3× 144 1.1× 36 0.5× 42 0.9× 20 256

Countries citing papers authored by MF Yuen

Since Specialization
Citations

This map shows the geographic impact of MF Yuen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by MF Yuen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites MF Yuen more than expected).

Fields of papers citing papers by MF Yuen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by MF Yuen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by MF Yuen. The network helps show where MF Yuen may publish in the future.

Co-authorship network of co-authors of MF Yuen

This figure shows the co-authorship network connecting the top 25 collaborators of MF Yuen. A scholar is included among the top collaborators of MF Yuen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with MF Yuen. MF Yuen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gane, Edward, MF Yuen, Christian Schwabe, et al.. (2018). RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated. Journal of Hepatology. 68. S101–S101. 23 indexed citations
3.
Yuen, MF, Bruce D. Given, Thomas Schluep, et al.. (2018). RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV. Journal of Hepatology. 68. S526–S526. 7 indexed citations
4.
Lai, Ching‐Lung, et al.. (2016). A population-based study on the seroprevalence of viral hepatitis in Hong Kong, China. Hepatology International. 2 indexed citations
5.
Wong, David, et al.. (2015). Reduction of hepatitis B core related antigen by long term nucleoside nucleotide analogue therapy and its correlation with intrahepatic HBV DNA reduction. Hepatology International. 4 indexed citations
6.
Kadayıfçı, Abdurrahman, George Papatheodoridis, MF Yuen, et al.. (2015). Characterization of HBsAg decline in the Tenofovir disoproxil fumarate (TDF) and peginterferon alfa 2A (PEG) combination study for chronic hepatitis B (CHB). Hepatology International. 1 indexed citations
7.
Lai, Ching‐Lung, et al.. (2015). Continuous entecavir for treatment naïve chinese chronic hepatitis B patients in the real world setting the seven year results. Hepatology International. 2 indexed citations
8.
Lai, Ching‐Lung & MF Yuen. (2015). Management of Chronic Hepatitis B in Patients from Special Populations. Cold Spring Harbor Perspectives in Medicine. 5(6). a021527–a021527. 2 indexed citations
9.
Fung, John J., Ksh Chok, William W. Sharr, et al.. (2012). Entecavir versus lamivudine prophylaxis without hepatitis B immune globulin after liver transplantation for chronic hepatitis B. Liver Transplantation. 1 indexed citations
10.
Fung, James, et al.. (2011). Elevation of ALT fails to predict significant histologic abnormalities in chronic hepatitis B patients. The HKU Scholars Hub (University of Hong Kong). 1 indexed citations
11.
Lam, Elegance T. P., et al.. (2009). Health-related quality of life of Southern Chinese with chronic hepatitis B infection. Health and Quality of Life Outcomes. 7(1). 52–52. 66 indexed citations
12.
Leung, Nancy, Cheng‐Yuan Peng, Jose D. Sollano, et al.. (2008). 998 ENTECAVIR (ETV) RESULTS IN HIGHER HBV DNA REDUCTION VERSUS ADEFOVIR (ADV) IN ANTIVIRAL-NAIVE HBEAG(+) ADULTS WITH HIGH HBVDNA: WEEK 96 RESULTS (E.A.R.L.Y. STUDY). Journal of Hepatology. 48. S373–S374. 10 indexed citations
13.
Terrault, Norah A., Solko W. Schalm, George Papatheodoridis, et al.. (2007). [483] PRESENCE OF BIOPSY-PROVEN HISTOLOGIC DAMAGE (NECROINFLAMMATION AND FIBROSIS) IS COMMON EVEN WHEN ALT IS LESS THAN 2 × ULN IN PATIENTS WITH CHRONIC HEPATITIS B (CHB). Journal of Hepatology. 46. S184–S184. 7 indexed citations
14.
Cheung, Johnny T. K., et al.. (2007). Decreasing Trend of Esophageal Adenocarcinoma in Hong Kong. Cancer Epidemiology Biomarkers & Prevention. 16(12). 2637–2640. 32 indexed citations
15.
Lai, Ching‐Lung, et al.. (2007). [108] LARGE POPULATION STUDY ON THE NATURAL HISTORY OF SPONTANEOUS HEPATITIS B E-ANTIGEN SEROCONVERSION: RISK OF HEPATOCELLULAR CARCINOMA. Journal of Hepatology. 46. S47–S48. 1 indexed citations
16.
Xia, Harry Hua‐Xiang, F. M. Y. Fung, Chee Kin Hui, et al.. (2005). Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician‐referred uninvestigated dyspeptic patients in Hong Kong. Alimentary Pharmacology & Therapeutics. 22(3). 243–249. 73 indexed citations
17.
Chu, Kent‐Man, W. M. Wong, Koon Chun Lai, et al.. (2003). A Prospective Comparison of Performance of Biopsy Forceps Used in Single Passage with Multiple Bites During Upper Endoscopy. Endoscopy. 35(4). 338–342. 7 indexed citations
18.
Wong, Bcy, W. M. Wong, F. M. Y. Fung, et al.. (2001). One‐week ranitidine bismuth citrate‐based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. Alimentary Pharmacology & Therapeutics. 15(3). 403–409. 24 indexed citations
19.
Yuen, MF, et al.. (2001). The accuracy of SM-HCV rapid test for the detection of antibody to hepatitis C virus. The American Journal of Gastroenterology. 96(3). 838–841. 12 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A.S. Lok Breakdown of academic impact, for papers by Samah Soliman Breakdown of academic impact, for papers by Michael K. K. Li Breakdown of academic impact, for papers by M. Forné Breakdown of academic impact, for papers by Blai Dalmau Breakdown of academic impact, for papers by Jérôme Filippi Breakdown of academic impact, for papers by Nasir Hassan Luck Breakdown of academic impact, for papers by Rekha Cheruvattath Breakdown of academic impact, for papers by Andrew Kirk Breakdown of academic impact, for papers by Jaya Agarwal
Rankless by CCL
2026